Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Jan 05, 2021 11:39am
192 Views
Post# 32223864

RE:RE:RE:RE:RE:RE:Betting on Friday ...

RE:RE:RE:RE:RE:RE:Betting on Friday ...
3burtc wrote: Well......... sorry just fuking with u! But you really don't believe an update is coming, do you? I mean they are obviously A - selling the company B - selling the drug C - a licensing deal Why give an update when we are on the verge of exiting this investment. It wouldn't make any sense.


Oh ... we're getting an update before J.P.Morgan.  That is absolutely the plan.
I'm betting it's on Friday ... that's all.

Don't forget ... Dan said a comprehensive update was just weeks away in Nov/Dec.
Our intel has narrowed it down to pre-J.P.Morgan.
I am assuming Friday.

Why would Dan do this?  He said he would focus on growing the company as he's negotiating.
The value of the business goes up with this two pronged approach.  There is no other way.
Plan for a multi-group partnership and anything else is just a bonus.

I expect an apology when the update comes through.

: )

<< Previous
Bullboard Posts
Next >>